此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

2026年8月5日 更新者：Genfleet Therapeutics (Shanghai) Inc.

A Phase III, Randomized, Open-Label, Multicenter Study to Evaluate GFH375 Versus Docetaxel in Participants With Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer With KRAS G12D Mutation Failed Prior Standard Therapy

The purpose of this study is to compare the effectiveness, safety and tolerability of GFH375 versus docetaxel in participants with KRAS G12D-mutant non-small cell lung cancer (NSCLC).

GFH375 is an oral, highly selective, non-covalent small-molecule inhibitor targeting the KRAS G12D mutation. Preclinical studies showed GFH375 strongly blocks KRAS-driven signaling and cancer cell growth, and demonstrated anti-tumor activity in NSCLC animal models. Docetaxel is a chemotherapy drug for locally advanced or metastatic NSCLC.

This is an open-label, randomized controlled trial. Both participant and study doctor will know which study medication each participant receives.

After enrollment, participant will be randomly assigned to either the GFH375 group or docetaxel group by chance. Neither participant nor study doctor can pick your treatment group. You have a two-thirds chance to receive GFH375 and a one-third chance to receive docetaxel.

  • GFH375 group: Take GFH375 tablets by mouth once daily as scheduled; each treatment cycle lasts 21 days.
  • Docetaxel group: Receive docetaxel via intravenous infusion at 75 mg/m² once every 3 weeks.

Study treatment will continue until cancer gets worse, participant can't tolerate the study treatment, or other conditions make participant unable to keep receiving study treatment.

Some participants on docetaxel may be able to switch to GFH375 during the study if their cancer becomes worse. There will be safety checks at each visit, and the doctors will continue to check for medical problems and participant 's wellbeing throughout the study. Participants will continue to have scans of their tumor every 6 weeks for the first year, then every 9 weeks until their cancer becomes worse. After participant's cancer becomes worse, clinic staff will telephone participant every 3 mouths to check on their cancer.

研究概览

地位

招聘中

条件

干预/治疗

研究类型

介入性

注册 (估计的)

300

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

  • 中国
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、201210
        • 招聘中
        • Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine
        • 接触：

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • 1. Voluntary participation in the study and signed informed consent form (ICF).
  • 2. Age ≥ 18 years at the time of signing the ICF; male or female.
  • 3. Histologically or cytologically confirmed locally advanced unresectable or metastatic non small cell lung cancer (NSCLC).
  • 4. Participants must provide adequate and qualified tumor tissue slides samples or agree to undergo tumor biopsy to obtain tissue samples for central laboratory confirmation of KRAS G12D mutation.
  • 5. Disease progression or intolerance to toxicity after at least one prior line of platinum based chemotherapy and anti PD 1/PD L1 antibody therapy.
  • 6. At least one measurable target lesion according to RECIST version 1.1.
  • 7. Investigator assessed life expectancy ≥ 12 weeks.
  • 8. Adequate organ function.
  • 9. Ability to communicate well, comply with scheduled follow up visits, and adhere to protocol requirements.

Exclusion Criteria:

  • 1. Presence of other driver gene mutations in NSCLC, or concurrent other KRAS or RAS mutations.
  • 2. Other malignancy that has progressed or required treatment within 3 years prior to randomization.
  • 3. Leptomeningeal metastasis, or symptomatic or progressive central nervous system (CNS) metastasis.
  • 4. Existing or potential severe bone injury due to bone metastasis, or uncontrolled pain related to bone metastasis.
  • 5. Prior treatment with KRAS G12D targeted therapy or pan RAS/KRAS targeted therapy.
  • 6. Prior treatment with docetaxel as part of systemic therapy.
  • 7. Radiotherapy within 4 weeks prior to randomization, or other local anti tumor therapy within 4 weeks prior to randomization.
  • 8. Other anti tumor therapy within 28 days or 5 half lives prior to randomization, or cell therapy within 3 months prior to randomization.
  • 9. Clinically significant severe cardiovascular disease.
  • 10. Stroke or other severe cerebrovascular disease within 6 months prior to randomization.
  • 11. Major acute or chronic infectious disease.
  • 12. Other poorly controlled systemic diseases.
  • 13. Severe psychiatric or psychological disorder, or history of drug abuse, or severe alcohol abuse.
  • 14. Pregnancy or breastfeeding.
  • 15. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：GFH375 group
Participants will take GFH375 orally once daily of every 21-day cycle.
药品：GFH375
GFH375 administered orally at the protocol-specified dose once daily. Each treatment cycle is 21 days.
有源比较器：Docetaxel group
Participants will receive docetaxel on day 1 of every 21-day cycle.
药品：Docetaxel
Receive docetaxel via intravenous infusion at 75 mg/m² once every 3 weeks.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Objective Response Rate(ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. as assessed by blinded independent central review (BICR)
大体时间：From the first dose until the date of first documented CR or PR, assessed up to 24 months
ORR is the proportion of participants whose best response is either complete response (CR) or partial response (PR) per RECIST v1.1 assessed by BICR.
From the first dose until the date of first documented CR or PR, assessed up to 24 months
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. as assessed by blinded independent central review (BICR)
大体时间：From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
PFS is defined as the time from the date of randomization until the date of documented radiographic disease progression per RECIST v1.1, as assessed by BICR or until death due to any cause, whichever comes first.
From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
Overall Survival (OS)
大体时间：From the first dose until the date of death from any cause, whichever came first, assessed up to 36~48 months
OS is defined as the time from the date of randomization until the date of death from any cause.
From the first dose until the date of death from any cause, whichever came first, assessed up to 36~48 months

次要结果测量

结果测量
措施说明
大体时间
Objective Response Rate (ORR) per RECIST v1.1, as assessed by the investigator
大体时间：From the first dose until the date of first documented CR or PR,assessed up to 24 months.
ORR is defined as the proportion of participants whose best overall response (BOR) is rated as confirmed complete response (CR) or confirmed partial response (PR) per RECIST v1.1. as assessed by the investigator.
From the first dose until the date of first documented CR or PR,assessed up to 24 months.
PFS per RECIST v1.1. as assessed by the investigator
大体时间：From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
PFS is defined as the time from the date of randomization until the date of documented radiographic disease progression per RECIST v1.1 as assessed by the investigator or until death due to any cause, whichever comes first.
From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
DCR per RECIST v 1.1 as assessed by the investigator and the BICR
大体时间：From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
DCR is defined as the proportion of participants whose best overall response is rated as CR, confirmed PR or SD per RECIST v1.1 as assessed by the investigator and the BICR.
From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
DoR per RECIST v 1.1 as assessed by the investigator and the BICR
大体时间：From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
DOR is defined as the time from the date of first documented response (CR or PR subsequently confirmed) to the date of first documented PD per RECIST v1.1 as assessed by the investigator and the BICR or death due to any cause, whichever occurs first.
From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
TTR per RECIST v 1.1 as assessed by the investigator and the BICR
大体时间：From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
TTR is defined as the time from the date of randomization to the first documentation of objective response (confirmed CR or confirmed PR) per RECIST v1.1. as assessed by the investigator and the BICR.
From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
Number of Participants with Adverse Events (AEs)
大体时间：From the first dose until 30 days after the last dose, assessed up to 24 months.
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
From the first dose until 30 days after the last dose, assessed up to 24 months.
Severity of Adverse Events(AEs)
大体时间：From the first dose until 30 days after the last dose, assessed up to 24 months.
The severity of an adverse event is commonly graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE )5.0.
From the first dose until 30 days after the last dose, assessed up to 24 months.
Incidence of AEs that result in treatment discontinuation, treatment interruption, or dose reduction.
大体时间：From the first dose until 30 days after the last dose, assessed up to 24 months.
AEs that result in treatment discontinuation, treatment interruption, or dose reduction.
From the first dose until 30 days after the last dose, assessed up to 24 months.
Severity of adverse events (AEs) leading to treatment discontinuation, treatment interruption, and dose reduction.
大体时间：From the first dose until 30 days after the last dose, assessed up to 24 months.
Severity of adverse events (AEs) leading to treatment discontinuation, treatment interruption, and dose reduction per CTCAE 5.0.
From the first dose until 30 days after the last dose, assessed up to 24 months.
Time to deterioration in NSCLC symptoms evaluated via European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) items
大体时间：From the first dose until 30 days after the last dose, assessed up to 24 months.
Time to deterioration is defined as time between randomization and the first occurrence of a meaningful deterioration in the corresponding EORTC QLQ-LC13 items score compared with the baseline score. EORTC QLQ-LC13 is a lung-cancer specific module that serves as an additional 13 item questionnaire to the general EORTC cancer questionnaire. It consists of 3 items to assess dyspnea, and 10 single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Scores range from 0 to 100. A high score for a symptom scale/item represents a high level of symptomatology/problems.
From the first dose until 30 days after the last dose, assessed up to 24 months.
Time to Worsening measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) items
大体时间：From the first dose until 30 days after the last dose, assessed up to 24 months.
Time to Worsening is defined as time between randomization and the first occurrence of a meaningful worsening in the composite EORTC QLQ-C30 items scores compared with the baseline score. EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For functional scales, higher scores indicate better functioning, while for symptom scales/items, higher scores indicate worse symptoms.
From the first dose until 30 days after the last dose, assessed up to 24 months.
Change from baseline in EORTC QLQ-C30
大体时间：From the first dose to week12.
The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For functional scales, higher scores indicate better functioning, while for symptom scales/items, higher scores indicate worse symptoms.
From the first dose to week12.
Change from baseline in EORTC QLQ-LC13
大体时间：From the first dose to week12.
EORTC QLQ-LC13 is a lung-cancer specific module that serves as an additional 13 item questionnaire to the general EORTC cancer questionnaire. It consists of 3 items to assess dyspnea, and 10 single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Scores range from 0 to 100. A high score for a symptom scale/item represents a high level of symptomatology/problems.
From the first dose to week12.
Pharmacokinetics (PK) of GFH375: Trough concentration after multiple dosing
大体时间：From the first dose to Cycle 6 Day 1(each cycle is 21 days).
Trough concentration will be recorded from plasma samples collected.
From the first dose to Cycle 6 Day 1(each cycle is 21 days).
PK of GFH375: Peak concentration after multiple dosing
大体时间：From the first dose to Cycle 6 Day 1(each cycle is 21 days).
Peak concentration will be recorded from plasma samples collected.
From the first dose to Cycle 6 Day 1(each cycle is 21 days).

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Genfleet Therapeutics (Shanghai) Inc.

调查人员

  • 首席研究员：Shun Lu, MD、Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月27日

初级完成 (估计的)

2030年6月30日

研究完成 (估计的)

2031年4月30日

研究注册日期

首次提交

2026年6月15日

首先提交符合 QC 标准的

2026年6月23日

首次发布 (实际的)

2026年6月25日

研究记录更新

最后更新发布 (实际的)

2026年8月10日

上次提交的符合 QC 标准的更新

2026年8月5日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • GFH375X1303

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅